When acute lymphocytic leukemia returns after initial treatment, patients face new challenges and decisions about managing the disease. Modern medicine offers a range of approaches to control symptoms, slow progression, and in many cases, achieve remission once again.

Hope and Strategy When Cancer Returns

Recurrent acute lymphocytic leukemia means that this blood cancer has come back after a person has undergone treatment and achieved remission. Between 15 and 20 percent of children who are treated for ALL experience a relapse, and in adults, the numbers can be higher. When ALL returns, it doesn’t mean that all hope is lost. Instead, it signals the need for a different treatment approach, one that takes into account why the previous therapy didn’t permanently eliminate all cancer cells.^[5]

Treatment for recurrent ALL depends heavily on several factors. These include how long the remission lasted before the cancer returned, the type of ALL (whether it affects B cells or T cells), the patient’s age and overall health, and whether the patient has already undergone certain intensive treatments like a stem cell transplant, which replaces damaged bone marrow with healthy stem cells. The goal of treatment can vary from achieving another complete remission to controlling the disease and reducing symptoms to maintain quality of life.^[10]

Medical teams approach recurrent ALL with a combination of established therapies and newer treatments that have emerged from clinical research. Some patients may respond well to repeating earlier chemotherapy regimens, especially if their first remission lasted a long time. Others may need completely different drugs or innovative approaches that weren’t available during their initial treatment. The landscape of ALL treatment has evolved significantly in recent years, offering more options than ever before.^[11]

Standard Treatment Approaches for Relapsed ALL

When ALL comes back, the first step is often reinduction chemotherapy, which means using anti-cancer drugs to try to achieve remission again. Chemotherapy works by targeting rapidly dividing cells, which includes cancer cells. If a patient’s remission lasted for a long period before relapse, doctors may use the same chemotherapy drugs that worked initially. However, if the remission was short, or if the cancer didn’t fully respond to the first treatment, different chemotherapy drugs or higher doses may be necessary.^[10]

For relapsed T-cell ALL, chemotherapy remains the primary treatment approach. The specific drugs chosen depend on what the patient received before and how their cancer cells responded. Some common chemotherapy agents used in ALL include vincristine, daunorubicin, cyclophosphamide, and methotrexate. These drugs can be given alone or in combinations designed to attack cancer cells through different mechanisms. The treatment typically continues in phases over several months, with regular monitoring through blood tests and bone marrow examinations to assess response.^[12]

Chemotherapy side effects can be significant and vary depending on the specific drugs used and the doses given. Common side effects include nausea and vomiting, hair loss, fatigue, increased risk of infections due to low white blood cell counts, anemia causing tiredness and weakness, and easy bruising or bleeding from low platelet counts. Some chemotherapy drugs can also affect the heart, kidneys, liver, or nervous system. Patients receive supportive care medications to help manage these side effects, including anti-nausea drugs, antibiotics to prevent or treat infections, and blood transfusions when needed.^[2]

For many patients with relapsed ALL who achieve another remission with chemotherapy, a stem cell transplant may be recommended. This procedure involves giving very high doses of chemotherapy, sometimes combined with radiation, to destroy all the cancer cells and the patient’s bone marrow. Then, healthy stem cells from a donor or from the patient’s own body (collected when in remission) are infused back into the bloodstream. These stem cells travel to the bone marrow and begin producing new, healthy blood cells. A stem cell transplant can offer a chance for long-term remission, but it carries significant risks including infections, graft-versus-host disease (when donor cells attack the patient’s body), and organ damage.^[10]

The duration of treatment for relapsed ALL varies widely. The initial reinduction phase, aimed at achieving remission, typically lasts several weeks to a few months. If remission is achieved, additional treatment phases called consolidation and maintenance therapy may continue for months or even years. The entire treatment journey can take two to three years or longer, depending on the patient’s response and whether complications arise. Throughout this time, patients undergo frequent monitoring with blood tests, bone marrow biopsies, and imaging studies to check how well the treatment is working.^[16]

Emerging Treatments Being Tested in Clinical Trials

One of the most promising developments in treating relapsed ALL is immunotherapy, which harnesses the power of the patient’s own immune system to fight cancer. For relapsed B-cell ALL, several immunotherapy approaches have shown remarkable results in clinical trials. These treatments work by helping the immune system recognize and attack leukemia cells that might otherwise hide from the body’s natural defenses.^[11]

CAR T-cell therapy represents a breakthrough in treating relapsed B-cell ALL. This innovative treatment involves collecting T cells (a type of immune cell) from the patient’s blood and genetically modifying them in a laboratory. The modification adds a special receptor called a chimeric antigen receptor, or CAR, to the T cells’ surface. This receptor is designed to recognize a protein called CD19 that sits on the surface of B-cell leukemia cells. Once the modified T cells are infused back into the patient, they multiply and hunt down cancer cells throughout the body, attaching to them and triggering their destruction.^[10]

One CAR T-cell therapy called tisagenlecleucel, marketed as KYMRIAH, has been approved for young adults up to age 25 with B-cell ALL that has relapsed or not responded to other treatments. Clinical trials have shown that this therapy can achieve remission in patients who had run out of other options. It may also be used for patients who cannot undergo a stem cell transplant due to medical reasons or lack of a suitable donor. The treatment is administered at specialized cancer centers that have been certified to provide this complex therapy.^[5][10]

CAR T-cell therapy can cause unique side effects that require careful monitoring. The most serious is cytokine release syndrome, which occurs when the modified T cells multiply rapidly and release large amounts of immune system chemicals into the bloodstream. This can cause high fever, low blood pressure, difficulty breathing, and organ dysfunction. Most patients experience some degree of this reaction, but medical teams are experienced in managing it with supportive care and specific medications. Another potential side effect involves temporary neurological symptoms such as confusion, difficulty speaking, or seizures. Despite these risks, many patients and families consider CAR T-cell therapy when other options have been exhausted.^[2]

Monoclonal antibodies are another form of immunotherapy being used for relapsed ALL. These are laboratory-made proteins designed to attach to specific targets on cancer cells. Two drugs in this category, blinatumomab and inotuzumab, have shown promising results in clinical trials for relapsed ALL and are now available in some healthcare systems. These drugs work by connecting cancer cells with immune cells, helping the immune system identify and destroy the leukemia cells. They tend to have fewer of the severe side effects associated with traditional chemotherapy, though they can still cause fatigue, infections, and other problems.^[13]

Clinical trials for relapsed ALL are exploring many other innovative approaches. Targeted therapy drugs are being tested that focus on specific genetic mutations or proteins found in leukemia cells. Unlike chemotherapy, which affects all rapidly dividing cells, targeted therapies are designed to attack cancer cells more precisely while sparing normal cells. This can potentially mean fewer side effects and better outcomes. Some of these drugs work by blocking signals that tell cancer cells to grow and divide, while others interfere with proteins that help cancer cells survive.^[2]

Clinical trials are conducted in phases. Phase I trials test a new treatment in a small group of people to evaluate its safety, determine a safe dosage range, and identify side effects. Phase II trials give the treatment to a larger group to see if it is effective and to further evaluate its safety. Phase III trials compare the new treatment to the current standard treatment to see which works better. Patients with relapsed ALL may be eligible for any of these phases depending on their specific situation and the trial’s requirements.^[3]

Many clinical trials for relapsed ALL are available across the United States, Europe, and other regions including Poland. Some trials are testing combinations of new drugs with standard chemotherapy, while others explore entirely new treatment approaches. Eligibility for these trials depends on factors such as the patient’s age, type of ALL, previous treatments received, overall health status, and specific genetic features of their leukemia cells. Patients interested in clinical trials should discuss options with their medical team, who can help identify appropriate studies and explain the potential benefits and risks.^[11]

Most common treatment methods

• Chemotherapy
  • Reinduction chemotherapy uses anti-cancer drugs to try to achieve remission again after relapse
  • Different drug combinations may be used depending on previous treatments and how long remission lasted
  • Common agents include vincristine, daunorubicin, cyclophosphamide, and methotrexate
  • Treatment continues in phases over several months with regular monitoring
  • Side effects include nausea, hair loss, fatigue, increased infection risk, and low blood counts
• Immunotherapy
  • CAR T-cell therapy modifies patient’s own T cells to recognize and attack leukemia cells
  • Tisagenlecleucel (KYMRIAH) is approved for relapsed B-cell ALL in patients up to age 25
  • Monoclonal antibodies like blinatumomab and inotuzumab help immune system destroy cancer cells
  • These treatments tend to have different side effects than traditional chemotherapy
• Stem cell transplant
  • May be recommended for patients who achieve remission after relapse
  • Involves high-dose chemotherapy or radiation followed by infusion of healthy stem cells
  • Can offer chance for long-term remission but carries significant risks
  • Requires specialized transplant center and careful post-transplant monitoring
• Targeted therapy
  • Drugs that focus on specific genetic mutations or proteins in leukemia cells
  • Tyrosine kinase inhibitors for Philadelphia chromosome positive ALL
  • Being tested in clinical trials for various ALL subtypes
  • Designed to attack cancer cells more precisely with potentially fewer side effects
• Central nervous system treatment
  • Chemotherapy delivered directly into spinal fluid through lumbar puncture
  • Radiation therapy directed at brain and spine when ALL has spread to central nervous system
  • Prevents or treats symptoms like headaches, seizures, and vision problems